TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04743661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omburtamab I-131
Description: Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy.
Study: NCT05029089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.
Description: Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.
Description: Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
Study: NCT05669534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.
Study: NCT05029089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)
Description: Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
Study: NCT04743661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omburtamab I-131
Description: Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy.
Study: NCT05669534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
Study: NCT04743661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSKI
Description: SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
Study: NCT05259605

Intervention type: OTHER
Intervention: Observational
Description: The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

Intervention type: OTHER
Intervention: Observational
Description: The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
Study: NCT04891484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron group
Description: patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline group
Description: patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
Study: NCT05037617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
Description: At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
Description: At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.
Study: NCT04761835

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peanut powder or peanut butter
Description: Commercially available peanut powder or peanut butter.
Study: NCT05029089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)
Description: Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)
Description: Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
Study: NCT05669534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
Study: NCT06151236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Description: Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
Study: NCT05503719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical wound closed with an absorbable suture
Description: Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical wound closed with a non-absorbable suture
Description: Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
Study: NCT05010889

Intervention type: PROCEDURE
Intervention: Peroral endoscopic myotomy (POEM)
Description: POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
Study: NCT04663555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
Study: NCT04949074

Intervention type: OTHER
Intervention: saliva sampling
Description: when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
Study: NCT04663555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
Study: NCT05372796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM
Description: instrument-assisted soft tissue mobilization
Study: NCT06348628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: 4 Motivational interviews within first 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Advices on standard of care treatment of NAFLD within first 6 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Advices on standard of care treatment of NAFLD within first 6 months
Study: NCT05526898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyntrFuge System
Description: Microsized Adipose Tissue

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Injection
Description: Corticosteroid
Study: NCT05776511

Intervention type: PROCEDURE
Group type: OTHER
Intervention: eVOG
Description: video digital oculography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: eVOG
Description: video digital oculography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: eVOG
Description: video digital oculography
Study: NCT05669534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
Study: NCT06550856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER
Description: Patients presented with perforated peptic ulcer will be repaired using full thickness suture closure using 3/0 vicryl suture then omental patch laied over the sutures.
Study: NCT05372796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise
Description: home exercise
Study: NCT06550856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER
Description: Patients presented with perforated peptic ulcer will be repaired by using omental patch without any attempt for primary closure of perforation.
Study: NCT04818034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
Study: NCT05627843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin capsules 1 gm
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: placebo corn starch
Study: NCT05623657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Stabilization Exercise Training Group
Description: The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game Based Exercise Program Group
Description: At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
Study: NCT05506527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor program and plyometric exercise
Description: Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~- Children of the study group B will receive sensorimotor program alone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor program and plyometric exercise
Description: Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~- Children of the study group B will receive sensorimotor program alone.
Study: NCT05372796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)
Description: OTES (Occipital Transcutenous Electric Stimulation)
Study: NCT05029089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
Study: NCT05599243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle excipient